Bausch Health (BHC) reported $2.52 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 11.7%. EPS of $0.78 for the same period compares to $0.59 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.41 billion, representing a surprise of +4.72%. The company delivered an EPS surprise of -3.11%, with the consensus EPS estimate being $0.81.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Diversified Products: $185 million versus the two-analyst average estimate of $218.61 million. The reported number represents a year-over-year change of -9.8%. Revenues- Bausch + Lomb- Vision Care: $711 million versus the two-analyst average estimate of $689.5 million. The reported number represents a year-over-year change of +8.4%. Revenues- Bausch + Lomb- Surgical: $228 million versus the two-analyst average estimate of $255.77 million. The reported number represents a year-over-year change of +6.5%. Revenues- Bausch + Lomb- Pharmaceuticals: $305 million compared to the $304.44 million average estimate based on two analysts. The reported number represents a change of +14.2% year over year. Revenues- International: $285 million versus the two-analyst average estimate of $271.83 million. The reported number represents a year-over-year change of +8.8%. Revenues- Diversified Products- Dermatology: $33 million versus $54.91 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -28.3% change. Revenues- Total Bausch + Lomb revenues: $1.24 billion versus $1.22 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.4% change. Revenues- Diversified Products- Neuroscience: $113 million compared to the $122.39 million average estimate based on two analysts. The reported number represents a change of -4.2% year over year. Revenues- Diversified Products- Generics: $18 million versus $18.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a 0% change. Revenues- Diversified Products- Dentistry: $21 million compared to the $22.98 million average estimate based on two analysts. The reported number represents a change of -8.7% year over year. Revenues- Salix: $639 million versus the two-analyst average estimate of $575.31 million. The reported number represents a year-over-year change of +17.9%. Revenues- Total Bausch Health (excl. B+L): $1.28 billion versus $1.19 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.1% change.View all Key Company Metrics for Bausch here>>>
Shares of Bausch have returned +5% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bausch Health Cos Inc. (BHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).